Overview
Constructive activist fund investing in public Chinese companies.
Founded
2015
Deals · 12mo
0
Links
Stage focus
Geographic focus
Sector focus
Investment portfolio
- Rege Nephro
Participated · Series A · Jan 2022
Rege Nephro is developing therapies for kidney disease and is advancing a clinical pipeline in the renal space. The company is preparing for clinical trials and is using interim financing to accelerate R&D and pipeline advancement. Its recent bridge financing is intended to extend cash runway and de-risk near-term development milestones ahead of a larger Series C. Rege Nephro says this capital raise is part of a longer-term strategy to strengthen its position in renal therapies. The company plans to pursue a Series C in autumn 2026 and beyond as it progresses clinical and development activities.